Literature DB >> 12052274

New biomarkers in the risk stratification of patients with suspected acute myocardial infarction.

Bret A Rogers1, L Kristin Newby.   

Abstract

The acute coronary syndromes (ACS) remain a diagnostic and prognostic challenge for today's physician. Over the past decade, studies have identified several serologic biomarkers to aid the clinician in assessing risk and predicting outcomes in ACS. Still others are being identified that show promise for increasing the accuracy with which this risk is assessed. However, further research remains necessary to identify the perfect cardiac biomarker or combination of markers and to define their roles in clinical management of ACS patients.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12052274     DOI： 10.1007/s11886-002-0071-z

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  28 in total

1.  Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes.

Authors:  F Ottani; M Galvani; F A Nicolini; D Ferrini; A Pozzati; G Di Pasquale; A S Jaffe
Journal:  Am Heart J       Date:  2000-12       Impact factor: 4.749

2.  Development of a simple whole blood panel test for detection of human heart-type fatty acid-binding protein.

Authors:  T Watanabe; Y Ohkubo; H Matsuoka; H Kimura; Y Sakai; Y Ohkaru; T Tanaka; Y Kitaura
Journal:  Clin Biochem       Date:  2001-06       Impact factor: 3.281

3.  Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial.

Authors:  C Heeschen; C W Hamm; J Bruemmer; M L Simoons
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

4.  Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB.

Authors:  F Okamoto; K Sohmiya; Y Ohkaru; K Kawamura; K Asayama; H Kimura; S Nishimura; H Ishii; N Sunahara; T Tanaka
Journal:  Clin Chem Lab Med       Date:  2000-03       Impact factor: 3.694

5.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.

Authors:  E Lindmark; E Diderholm; L Wallentin; A Siegbahn
Journal:  JAMA       Date:  2001-11-07       Impact factor: 56.272

6.  Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study.

Authors:  L K Newby; A B Storrow; W B Gibler; J L Garvey; J F Tucker; A L Kaplan; D H Schreiber; R H Tuttle; S E McNulty; E M Ohman
Journal:  Circulation       Date:  2001-04-10       Impact factor: 29.690

7.  Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.

Authors:  L Wallentin; B Lagerqvist; S Husted; F Kontny; E Ståhle; E Swahn
Journal:  Lancet       Date:  2000-07-01       Impact factor: 79.321

8.  A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report.

Authors:  D Bar-Or; E Lau; J V Winkler
Journal:  J Emerg Med       Date:  2000-11       Impact factor: 1.484

9.  Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.

Authors:  E M Antman; M J Tanasijevic; B Thompson; M Schactman; C H McCabe; C P Cannon; G A Fischer; A Y Fung; C Thompson; D Wybenga; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-31       Impact factor: 91.245

10.  Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators.

Authors:  E M Ohman; P W Armstrong; R H Christenson; C B Granger; H A Katus; C W Hamm; M A O'Hanesian; G S Wagner; N S Kleiman; F E Harrell; R M Califf; E J Topol
Journal:  N Engl J Med       Date:  1996-10-31       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.